# A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT01812746** · PHASE2 · COMPLETED · sponsor: **BIND Therapeutics** · enrollment: 42 (actual)

## Conditions studied

- CRPC
- Prostate Cancer

## Interventions

- **DRUG:** BIND-014

## Key facts

- **NCT ID:** NCT01812746
- **Lead sponsor:** BIND Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01812746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01812746, "A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01812746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*